Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.
Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center
Advertisement
Articles by Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center
Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.
Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.
Advertisement
Latest Updated Articles
Importance of Biomarker Testing for Solid TumorsPublished: March 31st 2021 | Updated:
Key Considerations for Biomarker TestingPublished: March 31st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5